184 related articles for article (PubMed ID: 38429685)
21. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
Patel S; Legood R; Evans DG; Turnbull C; Antoniou AC; Menon U; Jacobs I; Manchanda R
Am J Obstet Gynecol; 2018 Apr; 218(4):431.e1-431.e12. PubMed ID: 29288066
[TBL] [Abstract][Full Text] [Related]
23. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
[TBL] [Abstract][Full Text] [Related]
25. Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.
Yassaee VR; Zeinali S; Harirchi I; Jarvandi S; Mohagheghi MA; Hornby DP; Dalton A
Breast Cancer Res; 2002; 4(4):R6. PubMed ID: 12100744
[TBL] [Abstract][Full Text] [Related]
26. Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
Simoes Correa-Galendi J; Del Pilar Estevez Diz M; Stock S; Müller D
Appl Health Econ Health Policy; 2021 Jan; 19(1):97-109. PubMed ID: 32537695
[TBL] [Abstract][Full Text] [Related]
27. Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel.
Michaan N; Leshno M; Safra T; Sonnenblick A; Laskov I; Grisaru D
Cancer Prev Res (Phila); 2021 Apr; 14(4):455-462. PubMed ID: 33355193
[TBL] [Abstract][Full Text] [Related]
28. Knowledge, Practice, Preferences and Willingness-to-Pay for Mammographic Screening Tests among Iranian Women: A Contingent Valuation Method.
Karimabadi A; Pourahmadi E; Bafandeh Imandoust S; Nikoukar A; Aryafar M
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1207-1213. PubMed ID: 35485677
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness evaluation of risk-based breast cancer screening in Urban Hebei Province.
Shi J; Guan Y; Liang D; Li D; He Y; Liu Y
Sci Rep; 2023 Feb; 13(1):3370. PubMed ID: 36849794
[TBL] [Abstract][Full Text] [Related]
31. Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.
Wong ES; Shekar S; Chan CH; Hong LZ; Poon SY; Silla T; Lin C; Kumar V; Davila S; Voorhoeve M; Thike AA; Ho GH; Yap YS; Tan PH; Tan MH; Ang P; Lee AS
PLoS One; 2015; 10(7):e0134408. PubMed ID: 26221963
[TBL] [Abstract][Full Text] [Related]
32. Population-based Genetic Testing for Precision Prevention.
Evans O; Manchanda R
Cancer Prev Res (Phila); 2020 Aug; 13(8):643-648. PubMed ID: 32409595
[TBL] [Abstract][Full Text] [Related]
33. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
Pashayan N; Morris S; Gilbert FJ; Pharoah PDP
JAMA Oncol; 2018 Nov; 4(11):1504-1510. PubMed ID: 29978189
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review.
Koldehoff A; Danner M; Civello D; Rhiem K; Stock S; Müller D
Value Health; 2021 Feb; 24(2):303-312. PubMed ID: 33518037
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of mammography screening for breast cancer in a low socioeconomic group of Iranian women.
Barfar E; Rashidian A; Hosseini H; Nosratnejad S; Barooti E; Zendehdel K
Arch Iran Med; 2014 Apr; 17(4):241-5. PubMed ID: 24724599
[TBL] [Abstract][Full Text] [Related]
37. Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.
Lim KK; Yoon SY; Mohd Taib NA; Shabaruddin FH; Dahlui M; Woo YL; Thong MK; Teo SH; Chaiyakunapruk N
Appl Health Econ Health Policy; 2018 Jun; 16(3):395-406. PubMed ID: 29572724
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations.
Lipton JH; Zargar M; Warner E; Greenblatt EE; Lee E; Chan KKW; Wong WWL
Hum Reprod; 2020 Feb; 35(2):434-445. PubMed ID: 32099994
[TBL] [Abstract][Full Text] [Related]
39. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
[TBL] [Abstract][Full Text] [Related]
40. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
